Modifies provisions relating to health care
HB 1945 is a health care bill that combines three separate policy changes. First, it requires Missouri’s MO HealthNet Medicaid program to recognize the professional component of clinical pathology services provided by hospital-based pathologists as a distinct physician service and to reimburse that component at a minimum rate tied to the independent laboratory technical fee schedule. It also directs payment to the physician or an assignee and requires the Department of Social Services to seek any needed state plan amendment and adopt implementing rules.
Second, the bill revises Missouri’s pharmacy distribution licensing law by re-enacting section 338.333 and clarifying licensing requirements for wholesale drug distributors, pharmacy distributors, drug outsourcers, and third-party logistics providers. It preserves the board of pharmacy’s licensing authority, temporary licensure, reciprocity provisions, and separate site licensing rules, while updating terminology and cross-references.
Third, the bill adds a new insurance mandate for anesthesia services. It defines anesthesia time and anesthesia payment methodology, then prohibits health carriers and health benefit plans from imposing time limits on payment for anesthesia services or excluding anesthesia time from payment calculations. The mandate is extended to excepted benefit plans and applies broadly to state-regulated coverage, including MO HealthNet, CHIP, the Missouri consolidated health care plan, and other state-sponsored health insurance programs.
The bill’s impact is primarily on Medicaid reimbursement, pharmacy distribution regulation, and insurance payment practices. It would create a new statutory reimbursement obligation for MO HealthNet, potentially increase payments for hospital-based pathology services, and require administrative rulemaking and possible federal approval. It would also maintain and refine existing pharmacy licensure rules and impose new payment standards on insurers for anesthesia claims.
Overall, the bill appears to have been framed as a technical and provider-payment measure rather than a controversial overhaul, but its provisions affect multiple sectors of the health care system. The available record shows no committee transcript or recorded votes, so there is no documented floor debate or formal opposition in the provided materials. The most likely points of contention are the fiscal impact of mandated Medicaid and insurance reimbursements, the requirement that insurers pay for all anesthesia time, and the administrative burden of implementing new reimbursement and licensing rules.
HB 1945 would amend Missouri law by repealing and replacing section 338.333 and adding new sections 208.149 and 376.1245. It would require MO HealthNet to reimburse the professional component of clinical pathology services provided by hospital-based pathologists, set a minimum reimbursement floor, and direct payment procedures and rulemaking. It would also preserve and update pharmacy distributor licensing rules and impose new insurance payment requirements for anesthesia services across health carriers, health benefit plans, and certain state-sponsored coverage programs.
The provided materials do not include committee testimony or vote totals, so there is no direct record of debate sentiment. Based on the bill text, the measure appears to be a provider reimbursement and coverage standards bill with a practical health care administration focus. The absence of recorded opposition or amendment history in the supplied context suggests no clearly documented controversy in the available record, though the reimbursement mandates likely raise fiscal and insurer concerns.
The main likely points of contention are cost and administrative impact. MO HealthNet reimbursement for hospital-based pathology services could increase state Medicaid spending, and the anesthesia provisions would require carriers and plans to pay for all anesthesia time without imposing time caps, which insurers may view as a cost mandate. The pharmacy licensing changes are more technical, but any changes to reciprocity, temporary licensure, or site-specific licensing could draw attention from distributors and regulators. No specific opponents or supporters are identified in the provided transcripts or votes.